Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Stanford University
Ipsen
Brown University
Fred Hutchinson Cancer Center
Gilead Sciences
Aptevo Therapeutics
Massachusetts General Hospital